Results 1 to 10 of about 135,920 (249)

Who Is In Charge, and Who Should Be? The Disciplinary Role of the Commander in Military Justice Systems [PDF]

New England Journal of Medicine, 2006
BackgroundStandard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma ...
Abrey, Lauren, Brandes, Alba A., Carpentier, Antoine F., Cernea, Dana, Chinot, Olivier L., Cloughesy, Timothy, Henriksson, Roger, Hilton, Magalie, Hoang-Xuan, Khe, Kavan, Petr, Mason, Warren, Nishikawa, Ryo, Saran, Frank, Wick, Wolfgang   +13 more
core   +4 more sources

Lomustine and Bevacizumab in Progressive Glioblastoma

New England Journal of Medicine, 2017
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies.
W. Wick, T. Gorlia, M. Bendszus, M. Taphoorn, F. Sahm, I. Harting, A. Brandes, W. Taal, J. Dômont, A. Idbaih, M. Campone, P. Clement, R. Stupp, M. Fabbro, É. Le Rhun, F. Dubois, M. Weller, A. von Deimling, V. Golfinopoulos, Jacoline E. C. Bromberg, M. Plattén, M. Klein, M. J. van den Bent   +22 more
semanticscholar   +8 more sources

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [PDF]

Nature Network Boston, 2004
Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X Chen, Paul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain   +22 more
openalex   +2 more sources

Bevacizumab [PDF]

The Oncologist, 2010
AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to ...
Kazazi-Hyseni, F., Beijnen, J.H., Schellens, J.H.M.   +2 more
openaire   +6 more sources

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. [PDF]

, 2014
Preclinical studies demonstrate that epidermal growth factor receptor (EGFR) signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic. We
Bastida, Christel, Falchook, Gerald S, Fu, Siqing, Hess, Kenneth R, Hong, David S, Janku, Filip, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph   +11 more
core   +14 more sources

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine ...
J. Watanabe, K. Muro, K. Shitara, K. Yamazaki, M. Shiozawa, H. Ohori, A. Takashima, M. Yokota, A. Makiyama, N. Akazawa, H. Ojima, Y. Yuasa, K. Miwa, H. Yasui, E. Oki, Takeo Sato, Takeshi Naitoh, Y. Komatsu, T. Kato, M. Hihara, J. Soeda, T. Misumi, Kouji Yamamoto, K. Akagi, Atsushi Ochiai, H. Uetake, K. Tsuchihara, T. Yoshino   +27 more
semanticscholar   +1 more source

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Тазовая хирургия и онкология, 2021
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods.
M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin   +18 more
doaj   +1 more source

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic Advances in Medical Oncology, 2022
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data ...
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu   +12 more
doaj   +1 more source

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

Autophagy, 2023
Bevacizumab plays an important role in the first and second line treatment for metastatic colorectal cancer (CRC). And induction of hypoxia and the tumors response to it plays an important role in determining the efficacy of antiangiogenic therapy while ...
Weihao Li, Chi Zhou, Longjiang Yu, Zhenlin Hou, Huashan Liu, Lingheng Kong, Yanbo Xu, Jiahua He, Jin Lan, Q. Ou, Yujing Fang, Zhen-Hai Lu, Xiaojun Wu, Z. Pan, Jianhong Peng, Junzhong Lin   +15 more
semanticscholar   +1 more source

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab [PDF]

Journal of Cancer Research and Clinical Oncology, 2021
Abstract Purpose Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor-specific angiogenesis in some cancers. MYL-1402O is a proposed bevacizumab biosimilar. Methods The primary objective of this single-center, randomized,
Matthew Hummel, Tjerk Bosje, Andrew Shaw, Mark Shiyao Liu, Abhijit Barve, Mudgal Kothekar, Mark A. Socinski, Cornelius F. Waller   +7 more
openaire   +4 more sources